Pharmacyclics CEO takes aim at FDA decision-making

Dendreon isn't the only developer that has a beef with the FDA. Pharmalot writes up the case of Pharmacyclics CEO Richard Miller, who has found a soap box on some high profile news outlets to take the agency to task for rejecting the company's cancer drug. Miller's been on CNBC and on the op-ed pages of the Wall Street Journal to make the case that experimental drugs for terminal diseases should be treated differently than traditional meds.

"The FDA seems to be using a one-size-fits-all approach and seems to be regulating drugs that are intended for serious disease, life-threatening diseases, the same way they might regulate a drug that's used to treat a headache," says Miller.

- read the report from Pharmalot

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.